Upper Tract Urothelial Carcinoma VL

Nephron-Sparing Management of Low-Grade UTUC with UGN-101 (Mitomycin Gel) for Instillation: The Olympus Trial Experience - Seth Lerner

Details
Seth Lerner, the lead investigator for the Olympus Trial, joins Ashish Kamat to share the data that was presented at the 2019 AUA annual meeting regarding the Olympus Trial. The Olympus Trial was instrumental in the announcement by the FDA office granting priority review for the NDA for UGN-101, held by UroGen Pharma Ltd. This was a single-arm prospective phase 3 open-label study in patients with...

Biology and Genomic Distinctions in Metastatic Urothelial Carcinoma and Upper Tract Urothelial Cancers - Andrew Hsieh - Bishoy Faltas - Matthew Galsky

Details
Petros Grivas hosts Matthew Galsky, Bishoy Faltas and Andrew Hsieh in a discussion about their research programs and recent findings that drive closer to providing personalized medicine in the treatments in metastatic urothelial carcinoma and upper tract urothelial cancers. Groundbreaking work is discussed in this podcast and the three platform papers that discuss this evidence in more detail are...

SAUL Trial Data: Real World Experience of Atezolizumab in Carcinomas of the Urinary Tract- Cora Sternberg

Details
Cora Sternberg, MD and Alicia Morgans, MD discuss the SAUL (A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract) trial data which represents the "real world" experience with atezolizumab for the treatment of carcinomas of the urinary tract. The SAUL study enrolled patients that typically would be excluded from clinical trials includ...

Systemic Therapies in Upper Tract Urothelial Carcinoma - Srikala Sridhar

Details
Kala Sridhar provides a state of the-state in the contemporary understanding of upper tract disease, recent clinical trial findings and the impact of those trials on clinical practice treatment. Upper tract urothelial cancer (UTUC) accounts for approximately 5 - 7% of all urothelial cancers. At presentation about 60% of patients demonstrate invasive and/or locally advanced disease compared to abou...

Challenges in Immunotherapy for Bladder Cancer- Maria De Santis

Details
Maria De Santis discusses challenges in immunotherapy approaches for urothelial cancer with Alicia Morgans. One of the key challenges is understanding if the clinical trial data is translatable in daily practice due to the fact that most patients presenting with urothelial cancer are elderly. These patients tend to be over 70 years of age, have impaired renal function and decreased performance sta...

The Diagnostic and Therapeutic Challenges Associated with UTUC - Sam Chang

Details
Alicia Morgans and Sam Chang discuss the diagnostic and therapeutic challenges of upper tract urothelial carcinoma (UTUC). UTUC is relatively uncommon compared to urothelial carcinoma, accounting for 5-7% of all cases. The disease can be quite insidious and present a challenge to diagnose. Dr. Chang discusses the use of CT urograms in the diagnosis and how size, grade, and stage of the tumor is us...